Study identifies potential approach to treat patients with severe COVID-19

Posted · Add Comment
scidaily-logo-rss

Early data from a clinical study suggest that blocking the Bruton tyrosine kinase (BTK) protein with the cancer drug acalabrutinib provided clinical benefit to a small group of patients with severe COVID-19.

This full article appears on <a href="https://www.sciencedaily.com/releases/2020/06/200605140516.htm">Science Daily</a>

Leave a Reply

Your email address will not be published. Required fields are marked *